Johnson & Johnson (JNJ)

JNJ on New York Consolidated

103.13USD
24 Oct 2014
Price Change (% chg)

$0.50 (+0.49%)
Prev Close
$102.63
Open
$102.95
Day's High
$103.29
Day's Low
$102.21
Volume
5,973,242
Avg. Vol
7,247,314
52-wk High
$108.77
52-wk Low
$86.09

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products... (more)

Overall

Beta: 0.58
Market Cap (Mil.): $290,856.19
Shares Outstanding (Mil.): 2,820.29
Dividend: 0.70
Yield (%): 2.72

Financials

  JNJ Industry Sector
P/E (TTM): 17.09 33.21 34.06
EPS (TTM): 6.03 -- --
ROI: -- 18.18 17.45
ROE: -- 18.85 18.26
Search Stocks

NORDIC STOCKS - Factors to watch on Oct 24

OSLO, Oct 24 - The following stocks may be affected by newspaper reports and other factors on Friday:

24 Oct 2014

Johnson & Johnson's DePuy wins first trial over Pinnacle hips

NEW YORK/DALLAS - Johnson & Johnson was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company's DePuy Orthopedics unit were defective.

23 Oct 2014

UPDATE 2-Johnson & Johnson's DePuy wins first trial over Pinnacle hips

(Rewrites throughout, adds trial background and plaintiffs' lawyer quote, adds Dallas dateline)

23 Oct 2014

Johnson & Johnson's DePuy wins first trial over Pinnacle hips

NEW YORK, Oct 23 - Johnson & Johnson was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company's DePuy Orthopaedics unit were defective.

23 Oct 2014

J&J, GSK ready to collaborate on Ebola vaccine work

LONDON - Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration.

22 Oct 2014

J&J, GSK ready to collaborate on Ebola vaccine work

LONDON, Oct 22 - Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration.

22 Oct 2014

J&J and Bavarian Nordic expand production of an Ebola vaccine program

- Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

22 Oct 2014

J&J and Bavarian Nordic expand production of an Ebola vaccine program

Oct 22 - Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

22 Oct 2014

Jury deliberations begin in first trial over DePuy's Pinnacle hips

- A lawyer for a Montana woman on Tuesday urged jurors in a U.S. court to find Johnson & Johnson's DePuy Orthopedics unit liable for failing to warn patients that metal-on-metal Pinnacle hip implants were defective at the close of the first trial over the device.

21 Oct 2014

Jury deliberations begin in first trial over DePuy's Pinnacle hips

Oct 21 - A lawyer for a Montana woman on Tuesday urged jurors in a U.S. court to find Johnson & Johnson's DePuy Orthopaedics unit liable for failing to warn patients that metal-on-metal Pinnacle hip implants were defective at the close of the first trial over the device.

21 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks